Abstract
Signal transducer and activator of transcription 3 (STAT3) activation in cancer cells leads to immunosuppression and anti-apoptosis; inappropriate activation enables cancer cells to resist different treatment modalities. Systemic STAT3 inhibitors are currently in clinical trial testing. However, localized STAT3 inhibitors may be a promising option to decrease side-effects associated with systemic therapy. We previously reported that sonic stress delivered by low intensity focused ultrasound (LOFU) decreased constitutively active STAT3 levels in prostate cancer cells (PCa).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
